TCR2 Therapeutics Inc. (TCRR) — Financial statements
Income statement, balance sheet, and cash flow for TCR2 Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 99↑27.7% | 77↑48.6% | 52↑38.7% | 37↑90.6% | 20 | |
| General & Administrative Expenses | 24↑8.6% | 23↑34.6% | 17↑20.3% | 14↑104.9% | 7 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 24↑8.6% | 23↑34.6% | 17↑20.3% | 14↑104.9% | 7 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 123↑23.4% | 100↑45.2% | 69↑33.7% | 51↑94.2% | 26 | |
| Total Costs & Expenses | 123↑23.4% | 100↑45.2% | 69↑33.7% | 51↑94.2% | 26 | |
| Operating Results | ||||||
| Operating Income | -153↓53.9% | -100↓45.2% | -69↓33.7% | -51↓94.2% | -26 | |
| Depreciation & Amortization | 64↑2159.6% | 3↑77.6% | 2↑84.7% | 0.86↑105.7% | 0.42 | |
| EBITDA | -90↑7.5% | -97↓44.4% | -67↓32.8% | -51↓112.0% | -24 | |
| EBIT | -93↑7.1% | -100↓45.2% | -69↓33.7% | -51 | 0.00 | |
| Interest & Other Income | ||||||
| Net Interest Income | -57↓25527.7% | 0.22↓87.1% | 2 | 0.00 | 0.00 | |
| Interest Income | 2↑765.2% | 0.22↓87.1% | 2 | 0.00 | 0.00 | |
| Interest Expense | 59 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -61 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 2↑765.2% | 0.22↓87.1% | 2↓55.3% | 4↑76.4% | 2 | |
| Income Before Tax | -152↓52.3% | -100↓48.6% | -67↓41.0% | -47↓95.9% | -24 | |
| Income Tax Expense | 0.26↓9.7% | 0.29↑79.5% | 0.16↑57.8% | 0.10 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -152↓52.1% | -100↓48.7% | -67↓41.0% | -48↓96.3% | -24 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -152↓52.1% | -100↓48.7% | -67↓41.0% | -48↓96.3% | -24 | |
| Bottom-Line Net Income | -152↓52.1% | -100↓48.7% | -67↓41.0% | -48↓96.3% | -24 | |
| EPS (Basic) | -3.93↓49.4% | -2.63↓9.6% | -2.40↓6.2% | -2.26↓115.2% | -1.05 | |
| EPS (Diluted) | -3.93↓49.4% | -2.63↓9.6% | -2.40↓6.2% | -2.26↓115.2% | -1.05 | |
| Weighted Average Shares | 39↑1.8% | 38↑35.5% | 28↑32.6% | 21↓9.0% | 23 | |
| Weighted Average Diluted Shares | 39↑1.8% | 38↑35.5% | 28↑32.6% | 21↓9.0% | 23 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.